Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Date:9/8/2009

latin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website athttp://www.palatin.com.

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- News Facts , As the ... to genome-based research for human health and disease, the ... bite out of oral cancer with its world-class research into ... with the help of state-of-the-art solution comprising block, ... , To fuel its cutting-edge cancer research, the institute has ...
(Date:9/23/2014)... , Sept. 23, 2014   GenoSpace , ... comprehensive suite of tools to enable the broad use ... announced that it has been awarded Phase I of ... from the National Institutes of Health (NIH) to enable ... Logo - http://photos.prnewswire.com/prnh/20140922/147649 ...
(Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2
... Chiral Chemistry Adds to CML,s Technical ... ... Major Laboratories,announces the appointment of University of Illinois Professor John Hartwig,as ... of catalysis to the synthesis of amines, halogens, and a,variety of ...
... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or ... of Amarin, will present at the Acumen,BioFin Rodman & ... 12 noon Eastern time. The conference will be held ... New York. The presentation will be simultaneously webcast ...
... The Board of,Directors of Shire plc (LSE: SHP, ... announces today that David Mott will,join the Board ... Mr Mott is Chief Executive Officer and ... to in 2000. He joined MedImmune in 1992 ...
Cached Biology Technology:Cambridge Major Appoints Professor John Hartwig as Scientific Advisor 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 2Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference 3David Mott Appointed Non Executive Director at Shire 2David Mott Appointed Non Executive Director at Shire 3
(Date:9/22/2014)... (Sept. 22, 2014) As genetic sequencing technologies continue ... is a critical need to establish appropriate policies and ... experts have said. A special policy issue of the ... online today and edited by experts with the Center ... of Medicine gives policy makers the tools to jumpstart ...
(Date:9/22/2014)... key molecular cog in a plant,s biological clock ... based on temperature. , Transcription factors, or genetic switches, ... such as light, rain, soil quality, or even ... USC has isolated one, called FBH1, that reacts to ... needed while in keeping it on a consistent track. ...
(Date:9/22/2014)... in the country selected by the National Institutes ... Award a $2 million grant designed to ... sciences graduate trainees to career opportunities that go ... taken. , The award funds development of the ... program. It includes courses, seminars, shadowing, mentoring and ...
Breaking Biology News(10 mins):Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3Genetic switch regulates a plant's internal clock based on temperature 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... There are 300 million cases of malaria each year ... deaths occur in Africa, mostly in young children. One ... against malaria is drug resistance; resistance to chloroquine (CQ), ... throughout Africa, and resistance to sulfadoxine-pyrimethamine (SP), the first-developed ...
... detection system developed by Carnegie Mellon University scientists has ... to results being presented at the 36th Lunar and ... the first time a rover-based automated technology has been ... serves as a test bed for technology that could ...
... the bloodstream or under the skin to continuously monitor ... challenge for analytical chemists and biomedical engineers. The problem ... ways that interfere with their ability to accurately measure ... surface of implanted sensors or blood vessels contract around ...
Cached Biology News:Reducing malarial transmission in Africa 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 3Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 4Polymers with copper show promise for implanted sensors 2Polymers with copper show promise for implanted sensors 3
...
... T4 DNA Ligase catalyzes the formation ... ATP between double-stranded DNAs with 3' hydroxyl ... DNA Ligase buffer optimizes ligation which can ... nucleic acids are not substrates for this ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Biology Products: